Harvard Corporate Governance
OCTOBER 23, 2022
Posted by Brigid Rosati, Kilian Moote, Rajeev Kumar, Michael Maiolo, Georgeson LLC, on Sunday, October 23, 2022 Editor's Note: Brigid Rosati is Managing Director of Business Development; Rajeev Kumar is Senior Managing Director; Kilian Moote is Managing Director; and Michael Maiolo is a Senior Institutional Analyst at Georgeson. This post is based on a Georgeson memorandum by Ms.
Benzinga
OCTOBER 23, 2022
Myovant Sciences, Inc. (NYSE: MYOV ) announced late Sunday a deal to be acquired by Japanese pharmaceutical company Sumitomo Pharma Co., Ltd's (OTC: DNPUF ) unit Sumitovant Biopharma. The Deal Terms: The agreement provides for all of the Myovant shares to be acquired at $27 per share in cash, or $1.7 billion in total. The per-share value represents a 50% premium to Myovant’s closing price on Sept. 30, the last trading prior to the Japanese company’s non-binding proposal.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Harvard Corporate Governance
OCTOBER 23, 2022
Posted by Lawrence A. Cunningham (George Washington University), on Sunday, October 23, 2022 Editor's Note: Lawrence A. Cunningham is the Henry St. George Tucker III Research Professor at George Washington University Law School. Related research from the Program on Corporate Governance includes The Case Against Board Veto in Corporate Takeovers by Lucian A.
Reynolds Holding
OCTOBER 23, 2022
In the wake of the industry’s recent significant bankruptcy filings, crypto watchers are focusing for the first time on which crypto-entities are eligible for chapter 11 relief [1] under the U.S. Bankruptcy Code (the “ Bankruptcy Code ”) [2] and, if so, whether, and under what circumstances, crypto-assets held by the debtor may become property of the debtor’s “estate.” [3] As previously posted, if a customer’s crypto-assets are deemed part of the debtor’s estate, the customer may be treated as
Speaker: Susan Spencer, Principal of Spencer Communications
Intent signal data can go a long way toward shortening sales cycles and closing more deals. The challenge is deciding which is the best type of intent data to help your company meet its sales and marketing goals. In this webinar, Susan Spencer, fractional CMO and principal of Spencer Communications, will unpack the differences between contact-level and company-level intent signals.
Benzinga
OCTOBER 23, 2022
Please see below information about transactions made under the share buy-back program for Norsk Hydro ASA. Announcement date of the share buyback program: September 23, 2022. End date of the share buyback program: March 29, 2023. Overview of transactions: Date. Aggregate daily volume (no. of shares). Average price (NOK). Total transaction value (NOK). 17.10.2022. 163 000. 60.97. 9 938 077. 18.10.2022. 155 000.
Reynolds Holding
OCTOBER 23, 2022
On June 21, 2021, the International Monetary Fund (IMF) weighed in on the economic situation in Africa, and the news was not good. “African economies are at a pivotal juncture,” the IMF said. “The COVID-19 pandemic has brought economic activity to a standstill. Africa’s hard-won economic gains of the last two decades, critical in improving living standards, could be reversed.
Business Valuation Zone brings together the best content for business valuation professionals from the widest variety of industry thought leaders.
Benzinga
OCTOBER 23, 2022
Upfront consideration in cash of $0.34 per share representing a premium of approximately 42% over AGTC's closing stock price on October 21, 2022. Total consideration of up to $1.07, including up to $0.73 per CVR, representing a premium of up to approximately 344% over AGTC's closing stock price on October 21, 2022. AGTC's Board has examined all alternative options for the future of AGTC and believes this transaction clearly delivers the best value for shareholders.
Benzinga
OCTOBER 23, 2022
Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash. Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women's Health and Prostate Cancer. Agreement Unanimously Recommended by Special Committee of Myovant's Independent Directors and Approved by Board. NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd.
Expert insights. Personalized for you.
246 
Let's personalize your content